FDA Responds to SPAARx, Agrees to Delete "Specialty Pharmacy" from Compounding Legislation

Article

The FDA indicated in a letter to SPAARx that future compounding legislation will omit the term "specialty pharmacy."

The FDA indicated in a letter to SPAARx that future compounding legislation will omit the term “specialty pharmacy.”

In an effort to protect the interests of the specialty pharmacy industry, SPAARx reached out to the FDA in April and asked the agency to reconsider the use of the term “specialty pharmacy” interchangeably with the term “compounding” in future legislation.

According to an email from SPAARx, the FDA responded to the request this week. Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research, thanked SPAARx for bringing the issue to the FDA’s attention and noted that the agency is now actively involved with drafting the new legislation.

According to SPAARx, Dr. Woodcock wrote in a letter to SPAARx interim director Bill Sullivan that “drafts of this legislation now correctly define the issue" and apparently have deleted the specific use of the term 'specialty pharmacy.'

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.